Mesoblast reported fiscal year 2026 revenues of US$120.3 million, a significant increase from US$17.2 million in the prior year, driven by the first full year of commercialization for its FDA-approved product Ryoncil. Net product sales for Ryoncil reached US$115.2 million, generating approximately US$104 million in gross profit. The company reduced its net operating cash utilization to US$43.8 million and finished with cash reserves of US$102.9 million. Additionally, Mesoblast established a new US$125 million five-year non-dilutive credit facility to replace higher-cost debt and support future growth initiatives. Clinical milestones included completing enrollment in the pivotal Phase 3 trial for rexlemestrocel-L for chronic low back pain and commencing enrollment for Ryoncil in adults with SR-aGvHD. Mesoblast Limited is a global leader in allogeneic cellular medicines for inflammatory diseases.
